

BIOGRAPHICAL SKETCH

NAME: Michele Milella

POSITION TITLE: M.D., Full Professor of Oncology and Director, Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust (AOUI Verona), P.le L.A. Scuro 10, 37134 Verona, Italy

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)*

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
University of Rome "La Sapienza", Rome, Italy	MD	07/1992	Medicine and Surgery
University of Rome "La Sapienza", Rome, Italy	Medical license	02/1993	General Medicine
University of Rome "La Sapienza", Rome, Italy	Specialty	10/1996	Medical Oncology
University of Rome "La Sapienza", Rome, Italy	ECFMG	08/1998	General Medicine
USMLE, USA	certification		
	Postdoctoral Fellow	1999-2002	Signal transduction targeting as a therapeutic strategy in oncology
University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA			

A. Personal Statement

I am an experienced Medical Oncologist with a sincere passion for translational research. Since my beginnings in Medical School, I have been fascinated by the possibility that medicine could indeed become a "science", as much based on personal experience as on a deep understanding of the molecular and biological mechanisms underlying pathological processes and the action of drugs and therapeutic procedures. For this very reason, I followed the training path of a so-called "physician/scientist" over my entire career. During my internship, I trained in Immunology, gained substantial laboratory experience in the field of tumor immunology, and developed a keen interest in the molecular mechanisms of signal transduction regulating, for example, NK cell activation through the engagement of Fc receptors and integrins. Subsequently, I had a strong clinical training in medical oncology, where I tried to apply the methodological approach learned in the lab to complex clinical problems and to diagnostic and clinical reasoning. During my residency years, I gained substantial clinical experience in all fields of Oncology and developed a clinical/translational interest in anti-emetic treatment, H/N, breast, lung, and bladder cancer, spanning from the design and conduction of clinical trials of polychemotherapy to the application of gene transduction techniques to the immunotherapy of bladder cancer, using tumor cell-produced IL-2 for therapeutic purposes. At the same time, I tried to deepen my knowledge of the biostatistical methodology (mostly based on a classical frequentist approach) supporting the design and interpretation of clinical trials.

I subsequently enrolled in a postdoctoral fellowship in molecular hematology at the M. D. Anderson Cancer Center in Houston, where I was exposed to the fascination of probabilistic Bayesian approaches to statistical reasoning and started the line of research that has characterized my preclinical/translational activity to these days: targeting signaling intermediates (essentially the MAPK and PI3K/mTOR pathways) for therapeutic purposes in leukemias and solid tumors.

Upon my return in Rome, I went back to clinical oncology and developed a pancreatic cancer program at the Regina Elena National Cancer Institute where, over the years, I became responsible for the clinical management and research programs on hepato-bilio-pancreatic cancers, thoracic cancers, NET (including rarer forms such as Merkel cell carcinoma), and kidney cancer. Most recently, I contributed to the building of an AIFA certified Phase I/early phase clinical trial centre, in which I served as Medical Director.

In my new role as full professor of Oncology and director of Oncology at the University of Verona/AOUI Verona, my main objective has been to develop a new model of cancer medicine, whereby patient management and treatment decisions are guided by a profound knowledge of disease biology in individual patients. Molecular pathology, a keen attitude of the group to work in a multidisciplinary setting, and the translational tradition of my current environment, all concur to make the realization of an effective precision oncology program within reach at our Institution, giving us the possibility to change our clinical practice into a personalized, precise and humane "cancer science" centered on each individual patient.

B. Positions and Honors

1999-2002, Postdoctoral Fellow, Section of Molecular Hematology and Therapy, Dept. of Blood and Marrow Transplantation, University of Texas M. D. Anderson Cancer Center, Houston, TX;

2001-2018, Senior staff member, Attending physician; Division of Medical Oncology 1, Regina Elena National Cancer Institute, Rome;

2018, Medical Director Centro Studi Early Phase (CSEP) dedicated to phase I studies, Regina Elena National Cancer Institute, Rome;

2018-present, Full Professor of Oncology and Director of Oncology, University of Verona/AOUI Verona.

Honors

Winner, AIRC fellowship for Oncological Research (**1992**);

Degree's Thesis Award "Pasteur Institute - Cenci Bolognetti Foundation" (**1994**);

American Cancer Society International Fellowship for Beginning Investigators (ACSBI) administered by UICC (**1999/2000**);

Award of the National Committee for Biomedical Sciences (Italian National Research Council – CNR) (**1999**).

Scientific and Professional Societies' membership

- Italian Association for Medical Oncology (**AIOM**, since 1992), in which he also served as a member of the Guidelines on Diagnosis and Treatment of Pancreatic Cancer steering committee (2016/2020);
- Italian Society of Cancerology (**SIC**, since 2003);
- European Association for Cancer Research (**EACR**, since 2003);
- Italian Association for Neuroendocrine Tumors (**It.a.net**, since 2014);
- Scientific Committee of the Italian Foundation for Pancreatic Diseases (**FIMP**, since 2014);
- Elected Member of the Board of Directors, Italian Association for the Study of Pancreas (**AISP**, since 2016).

Editorial Board Memberships

World Journal of Gastroenterology (**Associate Editor**)

Journal of Experimental and Clinical Cancer Research (**Associate Editor**)

Frontiers in Gastrointestinal Sciences (specialty section of Frontiers in Physiology, **Review Editor**)

Current Pharmaceutical Design, Thematic issue: ***The lung and winding road: twists and turns on the way to personalized NSCLC therapy*** (Volume 20, Issue 24, 2014; **Guest Editor**)

Ad hoc reviewer for several international peer reviewed scientific journals and scientific projects' reviewer for the following international funding agencies: Biotechnology and Biological Sciences

Research Council (**UK**), AIRC (**Italy**), AIRC – Fellowship Scientific Committee (CSB, **Italy**), OENB Anniversary Fund (**Austria**), Austrian Science Fund (**Austria**), Institut National du Cancer (**France**), Italian Ministry of University and Scientific Research (**Italy**), Italian National Institutes of Health (ISS, **Italy**), Swiss Cancer League (**Switzerland**), Human Frontier Science Program (**France**), Prostate Cancer UK (**UK**).

C. Contributions to Science

Clinical research activity has been characterized by an interest in developing novel targeted therapy approaches, identifying and validating prognostic and predictive biomarkers, and developing meta-analytical approaches to evidence-based oncology, with special focus on: **pancreatic and hepato-biliary** cancers, **lung** cancer, **kidney** cancer, and **neuroendocrine** tumors. At the same time, I led a preclinical and translational group, whose research focus has been on the development new targeted drugs, particularly MAPK and PI3K/mTOR inhibitors, development of combinations of targeted drugs exploiting synergistic antitumor interactions, identification and validation of biomarkers of sensitivity/resistance to targeted treatments (with a focus on the potential role of PTEN), and most recently microenvironmental interactions between tumor and stromal cells.

Scopus Author ID: 7006373556

ORCID ID: 0000-0002-3826-5237

Researcher ID: K-5571-2018

Co-author of >250 publications in peer reviewed international journals.

h-Index: 50 (45 excluding self-citations from all authors).

Total citations: 14.288 (of which 8.450 in the past 5 years).

Source: *Scopus*, accessed Sep 20th, 2020.

43 publications in international journals are focused on pancreatic cancer.

D. Additional Information: Research Support and/or Scholastic Performance

Since 2002, Dr. Milella's research activity has been uninterruptedly funded by private and public institutions, such as Italian Association for Cancer Research (AIRC), Italian Ministry of Health, Cariplo Foundation, FIMP.

Verona, 07/06/22

A handwritten signature in black ink, consisting of a large, stylized capital letter 'M' followed by a smaller capital letter 'L' and a short horizontal stroke.

Curriculum Vitae Addendum

The undersigned declares that:
(please insert NA in each space if needed)

AFFILIATION

- At present I cover my role at the following Institution:

Institution name:	AOU VERONA
Department:	UOC ONCOLOGIA
Address:	P.le L.A. SCARLOTTA - VERONA
City (Prov.)- Postal code:	37134
Country:	Italy
Phone number: +39	045 812 8502
Fax number: +39	
Email address:	michele.milella@aoi.verona.it

GCP

- I am qualified by education and experience to assume responsibility for the proper conduct of trial and to have knowledge and to comply with the Good Clinical Practice (GCP)

Treatment of personal data

- I consent to the treatment of the personal data contained into my Curriculum Vitae according to the Regulation (EU) 2016/679 (General Data Protection Regulation - "GDPR").

Sincerely,

Printed Name: MICHELE MILELLA

Date (dd/mm/yyyy): 01/06/2018

Signature: _____